Viral Vectors And Plasmid DNA Manufacturing Market, By Product Type, By Therapeutic Application, By End Product, By Geography

Description

Viral Vectors And Plasmid DNA Manufacturing Market is estimated to be valued at USD 1,798.6 Mn in 2026 and is expected to reach USD 7,571.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 23% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,798.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	23.00%	2033 Value Projection:	USD 7,571.1 Mn

Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.

Market Dynamics

Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market

Market Segmentation

By Product Type
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
By Therapeutic Application
- Cancer
- Inherited Disorders
- Vitrectomy Surgery Devices
- Infectious Diseases
- Others
By End Product
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Lonza Group AG
- FinVector Vision Therapies
- Cobra Biologics and Pharmaceutical Services
- Sigma-Aldrich Co. LLC
- VGXI, Inc.
- VIROVEK
- SIRION Biotech GmbH
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Sanofi
- Cell and Gene Therapy Catapult
- Brammer Bio
- MassBiologics

Product Code: CMI962

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By End Product
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis of DROs
Comparative Analysis of Different Types of Viral Systems
Collaborations, Partnerships, And Agreements
Pipeline Analysis
New Product Launches
Investment Opportunities
Regulatory Scenario
Strategies For Product Development and Application Pathways
Brand Analysis
Cell & Gene Therapy Manufacturing Capacities Globally
Porter's Analysis

4. Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Viral Vector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
  - Retroviral Vectors
  - Adenoviral Vectors
  - Lentiviral Vectors
  - Adeno-associated Viral Vectors
  - Others
Plasma DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Non-Viral DNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Inherited Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
DNA Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2027
North America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Mn)
  - South Africa
  - Central Africa
  - North Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Lonza Group AG
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- FinVector Vision Therapies
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Cobra Biologics and Pharmaceutical Services
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Sigma-Aldrich Co. LLC
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- VGXI, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- VIROVEK
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- SIRION Biotech GmbH
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Sanofi
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Cell and Gene Therapy Catapult
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Brammer Bio
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- MassBiologics
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
  - Analyst Views

9. Section

References
Research Methodology
About Us and Sales Contact